Abstract: The present invention relates generally to methods for genetic modification of hematopoietic cells. In particular, the invention relates to use of Prostaglandin E2 (PGE2), poloxamer, and protamine sulfate to enhance transduction by a recombinant retroviral vector. The compositions and methods of the present disclosure are particularly suitable for gene therapy applications, including the treatment of monogenic genetic diseases and disorders.

Abstract: The present disclosure provides methods for manufacturing a recombinant lentiviral vectors in an adherent bioreactor, for example, by calcium-phosphate transfection of cells grown in adherent mode on low-compaction macrocarriers in an iCELLis® bioreactor system.

Abstract: In one embodiment, a method for applying body modifications to an avatar in a virtual world environment is defined. The method includes an operation to detect movement of the avatar into a facility that is a virtual world representation of a body modification facility. In another operation the method requests submission of a body modification to be applied to the avatar. The method also includes an operation to receive the submission of the body modification where the submission is a graphic illustration of the body modification. The method sends the submission of the body modification to a review process in order to monitor body modifications within the virtual world environment. In another operation, the method applies the body modification to the avatar once the body modification has passed the review process.